Celltrion's 'Remsima' Wins Brazilian Government Bids for 3 Consecutive Years... "Market Share Over 80%"

Celltrion Healthcare's biosimilar for autoimmune disease treatment, 'Remsima' (generic name infliximab), is strengthening its influence in the Latin American region, including achieving three consecutive years of success in winning federal government tenders in Brazil.

Celltrion's biosimilar for autoimmune disease treatment, 'Remsima'
Photo by Celltrion

Celltrion Healthcare announced on the 10th that Remsima has succeeded in winning the exclusive bid for the infliximab federal government tender in Brazil, the largest pharmaceutical market in Latin America, for three consecutive years. The federal government tender accounts for about 60% of the infliximab market in Brazil. Following two years of exclusive wins in the federal government's infliximab tenders, Celltrion Healthcare plans to supply 360,000 vials of Remsima in the first half of next year by winning this tender again.

Celltrion Healthcare has consistently worked to secure the Brazilian market, considered a key region for Latin American expansion. In addition to the federal government, the company has continuously participated in state government tenders, achieving consecutive wins in major states' infliximab tenders, starting with Minas Gerais in February, followed by Rio de Janeiro and Esp?rito Santo. When combining these public tenders with supplies to the private market, Remsima's market share in Brazil is expected to exceed 80%.

Remsima SC Model
Photo by Lee Chunhee

Synergy with 'RemsimaSC,' the subcutaneous injection (SC) formulation launched in July, is also becoming visible. In Europe, the strength of the 'dual formulation' strategy, where patients previously prescribed competing infliximab products switch to and maintain treatment with Remsima and RemsimaSC, has led to a simultaneous increase in market share for both products. Recently, RemsimaSC was also approved as a new drug in the United States. Celltrion Healthcare is continuing discussions with government agencies in Brazil to expand prescriptions of RemsimaSC.

Sales of Celltrion Healthcare's Brazil subsidiary have continued to grow, reaching KRW 49.7 billion in 2021, KRW 124.3 billion last year, and KRW 104.3 billion in cumulative sales through the third quarter this year. If the synergy between Remsima and RemsimaSC fully materializes, even steeper performance growth is expected.

Besides Brazil, the company plans to launch RemsimaSC in other Latin American countries such as Peru, Colombia, and Chile, aiming to steadily secure the market through the direct sales capabilities of local subsidiaries. With follow-up product launches scheduled for next year, including 'Yuflyma' (generic name adalimumab) and 'Vegzelma' (generic name bevacizumab), it is anticipated that market influence will be further strengthened through portfolio expansion.

Kang Kyung-doo, head of Celltrion Healthcare's Latin America region, said, "It is meaningful that Remsima has firmly established itself as the representative infliximab treatment in the Latin American market by winning the Brazilian federal government tender for three consecutive years." He added, "We will continue to strengthen our corporate capabilities to ensure the successful market entry of not only existing products such as 'Truxima' and 'Herzuma' but also upcoming follow-up products, and based on this, we will do our best to further expand the influence of Celltrion Group products in the Latin American region."

This content was produced with the assistance of AI translation services.